Several Hong Kong-listed companies have disclosed significant corporate actions, ranging from clinical trial launches and strategic partnerships to major contract wins and asset disposals. Meanwhile, a wave of interim earnings reports has been released, with mixed results across the healthcare, technology, and industrial sectors.

Key corporate developments

In the healthcare space, 石药集团 (CSPC Pharmaceutical Group) has officially initiated the first center in China for its Phase Ib/II clinical trial of SYS 6090 injection, which is being developed as a treatment for hepatocellular carcinoma. In the infrastructure sector, 中国铁建 (China Railway Construction Corp) recently secured a series of major projects with a combined contract value of RMB 44.31 billion. Meanwhile, 国药控股 (Sinopharm Group), together with its parent 国药集团 (Sinopharm) and 国药股份 (Sinopharm A-Think), has agreed to sell a combined 51% equity stake in Guorui Pharma for RMB 406 million. Additionally, 白云山 (Baiyunshan Pharmaceutical) subsidiary Tianxin Pharma has received the supplementary approval notice for its citicoline sodium injection (in 2ml:0.25g and 4ml:0.5g dosages). In technology, 基本半导体 (BASiC Semiconductor) has entered into a strategic cooperation agreement with 优必选 (UBTECH Robotics).

Interim earnings roundup

Turning to financial results, 洛阳钼业 (CMOC Group Limited) has posted its interim results with net profit attributable to shareholders reaching approximately RMB 16.152 billion, marking a significant increase of 86.27% year-on-year. The company has also declared an interim dividend of RMB 0.95 per 10 shares.

In the rail equipment sector, 中国中车 (CRRC Corp) reported interim net profit attributable to shareholders of about RMB 7.99 billion, up 10.28% from the previous year. 鼎泰高科 (Dingtai High-Tech) saw a substantial surge in earnings, with profit attributable to shareholders at RMB 679 million, a jump of 325.12% compared to the same period last year.

In the vaping industry, 思摩尔国际 (SMOORE International) announced an adjusted profit of approximately RMB 757 million for the interim period, up 2.6% year-on-year. Meanwhile, 赛力斯 (Seres) published its interim results, recording revenue of RMB 57.419 billion, reflecting sustained operational resilience. 时代电气 (CRRC Times Electric) reported net profit attributable to shareholders of about RMB 1.712 billion, a modest 2.44% increase.

Across the resources and materials sectors, 兖煤澳大利亚 (Yancoal Australia) posted a half-year net profit after tax attributable to shareholders of AUD 17 million, a sharp decline of 55% year-on-year. 天岳先进 (SICC) recorded interim revenue growth of 15.1% to RMB 914 million, driven by increased shipment volumes of large-sized products and ongoing optimization of its product mix.

In the software and cloud sectors, 金山软件 (Kingsoft) delivered interim net profit attributable to shareholders of RMB 1.639 billion, up 100.81% compared to the prior year. 光大证券 (Everbright Securities) reported interim net profit attributable to shareholders of RMB 2.229 billion, up 32.45%. 金山云 (Kingsoft Cloud) announced an adjusted EBITDA of RMB 1.848 billion for the interim period, a notable increase of 155.04%.

Finally, 荃信生物-B (Qyuns Biosciences) reported interim profit attributable to shareholders of RMB 203 million, achieving a turnaround from a loss in the same period last year. The company noted that its "Qyuns 1.0" strategic layout has now largely taken shape.